| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Anti-CD46 antibody drug conjugate (Fortis Therapeutics) | FG-3246; FOR-46 | Phase 2 Clinical | University Of California San Diego | Multiple Myeloma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 詳細 |
| Enadenotucirev | ColoAd-1; Oncolytic Ad11/Ad3 | Phase 1 Clinical | Akamis Bio Ltd | Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Colorectal Neoplasms; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | 詳細 |
| AugmAb | BRM-132 | Phase 1 Clinical | Compliment Corp | Lymphoma, Non-Hodgkin; Neoplasms | 詳細 |
| YS-5 | YS-5 | Phase 1 Clinical | Fortis Therapeutics Inc, United States Department Of Defense | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 詳細 |
| FG-3180 | 89Zr-DFO-YS-5; 89Zr-DFO-YS5 | Phase 1 Clinical | Fortis Therapeutics Inc | Multiple Myeloma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 詳細 |